Edwards bumps up sales forecast on TAVR strength in Q3

Edwards Lifesciences raised its sales forecast following strong Q3 performance in transcatheter aortic valve replacement (TAVR) procedures. The company expects procedure volumes to continue rising based on positive study data and expanded Medicare reimbursement.